These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 16447119)

  • 21. Predictive factors of treatment interruption duration in a cohort of HIV-1 infected patients with CD4 count greater than 350 cells per mm3.
    Fillaux J; Delpierre C; Alvarez M; Jaafar A; Marchou B; Massip P; Cuzin L
    Med Mal Infect; 2006 Jun; 36(6):335-9. PubMed ID: 16631330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD).
    Zhou J; Kumarasamy N;
    HIV Med; 2005 May; 6(3):216-23. PubMed ID: 15876289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
    Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
    Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia.
    Sabin CA; Lepri AC; Devereux H; Phillips AN; Loveday C; Lee CA
    J Infect Dis; 2001 Aug; 184(4):511-4. PubMed ID: 11471111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS.
    Berrey MM; Schacker T; Collier AC; Shea T; Brodie SJ; Mayers D; Coombs R; Krieger J; Chun TW; Fauci A; Self SG; Corey L
    J Infect Dis; 2001 May; 183(10):1466-75. PubMed ID: 11319682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
    Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
    Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
    Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
    Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
    AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count.
    Mañas E; Pulido F; Peña JM; Rubio R; Gonzalez-García J; Costa R; Pérez-Rodríguez E; Del Palacio A
    Int J Tuberc Lung Dis; 2004 Apr; 8(4):451-7. PubMed ID: 15141738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No evidence of a change in HIV-1 virulence since 1996 in France.
    Troude P; Chaix ML; Tran L; Deveau C; Seng R; Delfraissy JF; Rouzioux C; Goujard C; Meyer L;
    AIDS; 2009 Jun; 23(10):1261-7. PubMed ID: 19424055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
    Miller V; Phillips AN; Clotet B; Mocroft A; Ledergerber B; Kirk O; Ormaasen V; Gargalianos-Kakolyris P; Vella S; Lundgren JD
    J Infect Dis; 2002 Jul; 186(2):189-97. PubMed ID: 12134254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
    Miro JM; Lopez JC; Podzamczer D; Peña JM; Alberdi JC; Martínez E; Domingo P; Cosin J; Claramonte X; Arribas JR; Santín M; Ribera E;
    Clin Infect Dis; 2006 Jul; 43(1):79-89. PubMed ID: 16758422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Quantification of viremia in patients infected with human immunodeficiency virus with different degrees of immunosuppression].
    Soriano V; Gómez-Cano M; Mas A; Villalba N; Castilla J; Adrados M; Laguna F; Polo R; González-Lahoz J
    Rev Clin Esp; 1997 Dec; 197(12):810-3. PubMed ID: 9477671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.